Engitix is using its proprietary human organ decellularisation technology to develop tissue engineered products for application in regenerative medicine and drug-target research. Engitix’ core expertise is treatment and research of liver disease using its proprietary technologies for human extra-cellular matrix (ECM) scaffolds and 3D spheroids for bioartificial liver devices. The scaffold technology is applicable to other organs and disease aetiologies including pancreatic and intestine scaffold products.